Phthalate exposure changes the metabolic profile of cardiac muscle cells

Environmental Health Perspectives

Volumn 120, Issue 9, 2012, Pages 1243-1251

  Posnack, Nikki Gillum ^a   Swift, Luther M ^a   Kay, Matthew W ^a,b   Lee, Norman H ^a   Sarvazyan, Narine ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b George Washington University   (United States)

Author keywords

Cardiomyocyte; di(2 ethylhexyl)phthalate; Fatty acid metabolism; Microarray; Plasticizer

Indexed keywords

CD36 ANTIGEN; FATTY ACID BINDING PROTEIN 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR ALPHA; PHTHALIC ACID BIS (2 ETHYLHEXYL) ESTER; PIRINIXIC ACID; PYRUVATE DEHYDROGENASE KINASE 4; UNCLASSIFIED DRUG;

ACIDOSIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ESTERIFICATION; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENE EXPRESSION; HEART MUSCLE CELL; IMMUNOCYTOCHEMISTRY; MICROARRAY ANALYSIS; MITOCHONDRION; NEWBORN; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

RATTUS;

ANIMALS; BLOTTING, WESTERN; DIETHYLHEXYL PHTHALATE; ENVIRONMENTAL POLLUTANTS; FATTY ACIDS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; GLUCOSE; IMMUNOHISTOCHEMISTRY; MITOCHONDRIA; MYOCYTES, CARDIAC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLASTICIZERS; PPAR ALPHA; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; TISSUE ARRAY ANALYSIS;

EID: 84930486272     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1205056     Document Type: Article

References (39)

1. Arutunyan A, Webster DR, Swift LM, Sarvazyan N. 2001. Localized injury in cardiomyocyte network: a new experimental model of ischemia-reperfusion arrhythmias. Am J Physiol Heart Circ Physiol 280(4):H1905-H1915.
2. Bility MT, Thompson JT, McKee RH, David RM, Butala JH, Vanden Heuvel JP, et al. 2004. Activation of mouse and human peroxisome proliferator-activated receptors (PPARs) by phthalate monoesters. Toxicol Sci 82(1):170-182.
3. Burri L, Thoresen GH, Berge RK. 2010. The role of PPARα activation in liver and muscle. PPAR Res 2010:542359; doi:10.1155/2010/542359 [Online 18 August 2010].
4. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JR, Belke DD, et al. 2002. A role for peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARα are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277(6):4098-4103.
5. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S. et al. 2009. AmiGO: online access to ontology and annotation data. Bioinformatics 25(2):288-289.
6. Carlson K. 2010. Memorandum from KR Carlson, U.S. Consumer Product Safety Commision, to MA Babich, U.S. Consumer Product Safety Commision. Toxicity Review of Di(2-ethylhexyl) Phthalate (DEHP), 1 April 2010. Available: http://www.cpsc.gov/about/cpsia/toxicityDEHP.pdf [accessed 3 June 2012].
7. Casals-Casas C, Desvergne B. 2011. Endocrine disruptors: from endocrine to metabolic disruption. Annu Rev Physiol 73:135-162.
8. Chambers KT, Leone TC, Sambandam N, Kovacs A, Wagg CS, Lopaschuk GD, et al. 2011. Chronic inhibition of pyruvate dehydrogenase in heart triggers an adaptive metabolic response. J Biol Chem 286(13):11155-11162.
9. Chanda D, Lee CH, Kim YH, Noh JR, Kim DK, Park JH, et al. 2009. Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner. Hepatology 50(3):880-892.
10. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, et al. 2001. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest 107(7):813-822.
11. Desvergne B, Feige JN, Casals-Casas C. 2009. PPAR-mediated activity of phthalates: a link to the obesity epidemic? Mol Cell Endocrinol 304(1-2):43-48.
12. Durgan DJ, Smith JK, Hotze MA, Egbejimi O, Cuthbert KD, Zaha VG, et al. 2006. Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am J Physiol Heart Circ Physiol 290(6):H2480-H2497.
13. Edgar R, Domrachev M, Lash AE. 2002. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30(1):207-210.
14. Ellero-Simatos S, Claus SP, Benelli C, Forest C, Letourneur F, Cagnard N, et al. 2011. Combined transcriptomic-1HNMR metabonomic study reveals that monoethylhexyl phthalate stimulates adipogenesis and glyceroneogenesis in human adipocytes. J Proteome Res 10(12):5493-5502.
15. Ervin RB. 2009. Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006. Natl Health Stat Report 13:1-7.
16. FDA (Food and Drug Administration). 2002. Safety Assessment of Di(2-Ethylhexyl)Phthalate (DEHP) Released from PVC Medical Devices. Available: http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm080457.pdf [accessed 3 June 2012].
17. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, et al. 2002. The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest 109(1):121-130.
18. Gao L, Wang J, Sekhar KR, Yin H, Yared NF, Schneider SN, et al. 2007. Novel n-3 fatty acid oxidation products activate Nrf2 by destabilizing the association between Keap1 and Cullin3. J Biol Chem 282(4):2529-2537.
19. Gillum N, Karabekian Z, Swift LM, Brown RP, Kay MW, Sarvazyan N. 2009. Clinically relevant concentrations of di(2-ethylhexyl) phthalate (DEHP) uncouple cardiac syncytium. Toxicol Appl Pharmacol 236(1):25-38.
20. Henin N, Vincent MF, Gruber HE, Van den Berghe G. 1995. Inhibition of fatty acid and cholesterol synthesis by stimulation of AMP-activated protein kinase. FASEB J 9(7):541-546.
21. Hillman LS, Goodwin SL, Sherman WR. 1975. Identification and measurement of plasticizer in neonatal tissues after umbilical catheters and blood products. N Engl J Med 292(8):381-386.
22. Ito Y, Yamanoshita O, Asaeda N, Tagawa Y, Lee CH, Aoyama T, et al. 2007. Di(2-ethylhexyl)phthalate induces hepatic tumorigenesis through a peroxisome proliferator-activated receptor α-independent pathway. J Occup Health 49(3):172-182.
23. Itsuki-Yoneda A, Kimoto M, Tsuji H, Hiemori M, Yamashita H. 2007. Effect of a hypolipidemic drug, di (2-ethylhexyl) phthalate, on mRNA-expression associated fatty acid and acetate metabolism in rat tissues. Biosci Biotechnol Biochem 71(2):414-420.
24. Jager S, Handschin C, St-Pierre J, Spiegelman BM. 2007. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci USA 104(29):12017-12022.
25. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC. 2010. Myocardial fatty acid metabolism in health and disease. Physiol Rev 90(1):207-258.
26. Martinelli MI, Mocchiutti NO, Bernal CA. 2006. Dietary di(2-ethylhexyl)phthalate-impaired glucose metabolism in experimental animals. Hum Exp Toxicol 25(9):531-538.
27. Peters JM, Taubeneck MW, Keen CL, Gonzalez FJ. 1997. Di(2-ethylhexyl) phthalate induces a functional zinc deficiency during pregnancy and teratogenesis that is independent of peroxisome proliferator-activated receptor-α. Teratology 56(5):311-316.
28. Posnack NG, Lee NH, Brown R, Sarvazyan N. 2011. Gene expression profiling of DEHP-treated cardiomyocytes reveals potential causes of phthalate arrhythmogenicity. Toxicology 279(1-3):54-64.
29. Randle PJ, Garland PB, Hales CN, Newsholme EA. 1963. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1(7285):785-789.
30. Ren H, Aleksunes LM, Wood C, Vallanat B, George MH, Klaassen CD, et al. 2010. Characterization of peroxisome proliferator-activated receptor α-independent effects of PPARα activators in the rodent liver: di-(2-ethylhexyl) phthalate also activates the constitutive-activated receptor. Toxicol Sci 113(1):45-59.
31. Reubsaet FA, Veerkamp JH, Dirven HA, Bruckwilder ML, Hashimoto T, Trijbels JM, et al. 1990. The effect of di(ethylhexyl)phthalate on fatty acid oxidation and carnitine palmitoyltransferase in various rat tissues. Biochim Biophys Acta 1047(3):264-270.
32. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, et al. 2006. TM4 microarray software suite. Methods Enzymol 411:134-193.
33. Stahlhut RW, van Wijngaarden E, Dye TD, Cook S, Swan SH. 2007. Concentrations of urinary phthalate metabolites are associated with increased waist circumference and insulin resistance in adult U.S. males. Environ Health Perspect 115:876-882.
34. Svensson K, Hernandez-Ramirez RU, Burguete-Garcia A, Cebrian ME, Calafat AM, Needham LL, et al. 2011. Phthalate exposure associated with self-reported diabetes among Mexican women. Environ Res 111(6):792-796.
35. Swan SH. 2008. Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans. Environ Res 108(2):177-184.
36. van Iersel MP, Kelder T, Pico AR, Hanspers K, Coort S, Conklin BR, et al. 2008. Presenting and exploring biological pathways with PathVisio. BMC Bioinformatics 9:399; doi:10.1186/1471-2105-9-399 [Online 25 September 2008.]
37. Ward JM, Peters JM, Perella CM, Gonzalez FJ. 1998. Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor α-null mice. Toxicol Pathol 26(2):240-246.
38. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, et al. 1999. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98(1):115-124.
39. Zungu M, Young ME, Stanley WC, Essop MF. 2009. Chronic treatment with the peroxisome proliferator-activated receptor α agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function. Mol Cell Biochem 330(1-2):55-62.